meloxicam
food
drug
administr
approv
product
daili
oral
parenter
administr
dog
boehring
ingelheim
norbrook
nonsteroid
drug
nsaid
higher
select
sever
speci
inhibitori
activ
analges
commonli
select
research
mice
complianc
guid
care
use
laboratori
anim
edit
nation
research
council
us
committe
updat
guid
care
use
laboratori
anim
current
industri
standard
practic
provid
analgesia
procedur
expect
caus
momentari
pain
distress
base
search
public
access
univers
formulari
analges
appar
wide
dosag
rang
mice
mgkg
everi
h
commonli
use
dosag
mgkg
everi
h
anim
care
use
program
ucsf
boston
univers
john
hopkin
univers
portland
va
univers
british
columbia
univers
pennsylvania
recommend
dosag
mice
base
postprocedur
physiolog
behavior
paramet
date
limit
inform
correl
dose
plasma
concentr
tubb
et
al
miller
et
al
ratsep
et
al
kendal
et
al
common
practic
research
set
provid
h
postprocedur
analgesia
invas
procedur
meloxicam
common
drug
choic
often
administ
interv
purpos
studi
character
plasma
concentr
meloxicam
given
interv
h
male
femal
mice
compar
time
valu
refer
inhibit
constant
meloxicam
data
male
femal
mice
also
compar
gender
differ
meloxicam
pharmacokinet
subcutan
administr
current
unknown
consider
import
address
state
nation
institut
health
polici
preclin
research
clayton
collin
mice
chosen
strain
repres
commonli
use
diseas
model
project
approv
institut
anim
care
use
committe
vanderbilt
univers
medic
center
associ
assess
accredit
laboratori
anim
care
intern
accredit
institut
mice
gender
purchas
studi
exclud
pathogen
mous
coloni
includ
mous
parvovirus
murin
noroviru
mous
coronaviru
mous
rotaviru
mous
theiloviru
adenoviru
type
reoviru
type
pneumonia
viru
mice
sendai
viru
lymphocyt
choriomening
viru
ectromelia
helicobact
citrobact
mycoplasma
pulmoni
corynebacterium
kutscheria
corynebacterium
bovi
giardia
pneumocysti
spironucleu
muri
pinworm
myobia
myocopt
radfordia
fur
mite
aspiculuri
syphacia
mice
acclim
hous
facil
day
prior
drug
administr
gender
three
mice
per
ventil
cage
xj
mous
cage
allentown
incorpor
allentown
nj
usa
bed
anderson
incorpor
maume
oh
usa
autoclav
individu
ventil
air
chang
per
hour
humid
rang
room
maintain
light
dark
cycl
mice
receiv
irradi
food
labdiet
high
energi
mous
diet
st
loui
mo
usa
autoclav
water
ad
lib
control
male
mous
plasma
use
bioanalysi
acquir
bioreclamationivt
upstat
ny
usa
liquid
spectrometri
lcm
grade
acetonitril
acn
dimethyl
sulfoxid
formic
acid
acquir
fisher
scientif
waltham
usa
meloxicam
piroxicam
standard
obtain
lkt
laboratori
saint
paul
mn
usa
st
loui
mo
usa
respect
studi
design
longitudin
random
nonseri
male
femal
mice
divid
four
group
male
group
femal
group
group
contain
sampl
size
six
mice
three
day
prior
drug
administr
mice
ear
punch
bodi
weight
measur
studi
weight
obtain
daili
time
sacrific
overal
weight
male
mice
averag
g
rang
g
femal
averag
g
rang
g
meloxicam
mgml
norbrook
dilut
steril
salin
concentr
mgml
mice
anesthet
isofluran
receiv
three
subcutan
inject
meloxicam
mgkg
ml
h
time
point
subcutan
inject
administ
midlin
scapular
region
three
blood
sampl
collect
mous
variou
time
point
h
follow
first
inject
sequenti
blood
collect
time
point
mous
base
maxim
rest
period
sampl
collect
address
individu
anim
welfar
mous
underw
two
surviv
one
termin
blood
collect
procedur
surviv
sampl
total
exceed
anim
total
blood
volum
submandibular
surviv
sampl
collect
consciou
anim
lancet
goldenrod
anim
lancet
mm
point
length
blood
sampl
collect
time
calcul
first
meloxicam
administr
sampl
collect
six
male
six
femal
mice
h
blood
collect
group
one
five
h
group
two
six
h
group
three
seven
h
group
four
eight
h
termin
blood
sampl
collect
cardiac
punctur
mice
anesthet
isofluran
time
point
h
sampl
collect
ethylenediaminetetraacet
acid
vial
skin
sampl
collect
time
point
includ
group
two
six
tissu
sampl
collect
scapular
area
fix
buffer
formalin
mice
human
euthan
evalu
grossli
skin
lesion
skin
inject
site
collect
orient
flat
index
card
fix
neutral
buffer
formalin
tissu
process
routin
embed
paraffin
section
four
micron
stain
hematoxylin
eosin
stain
evalu
pathologist
klb
board
certifi
american
colleg
veterinari
pathologist
experienc
examin
murin
skin
sampl
plasma
concentr
time
point
compar
use
tabl
comparison
cmax
ob
cmin
ob
mean
plasma
concentr
valu
tabl
comparison
gender
cmax
ob
cmin
ob
mean
plasma
concentr
valu
pair
use
serial
data
point
compar
h
tabl
unpair
welch
correct
util
nonseri
data
involv
time
point
comparison
tabl
standard
meloxicam
prepar
dilut
fresh
mgml
dimethyl
sulfoxid
solut
blank
mous
plasma
follow
plasma
dilut
give
rang
ngml
twenti
microlit
volum
standard
studi
plasma
sampl
dilut
mous
plasma
precipit
four
volum
acn
contain
nm
piroxicam
intern
standard
sampl
next
centrifug
g
refriger
centrifug
min
sixti
microlit
volum
supernat
ad
equal
volum
water
inject
plate
seal
place
refriger
autosampl
analysi
sampl
analyz
lcmsm
inject
onto
shimadzu
liquid
chromatographi
system
forti
technolog
ltd
mm
column
cheshir
uk
coupl
ab
sciex
mass
spectromet
oper
posit
mode
framingham
usa
initi
mobil
phase
condit
vv
formic
acid
water
acetonitril
inject
solvent
gradient
initi
acetonitril
min
held
min
follow
return
start
condit
equilibr
mass
spectromet
condit
dwell
time
ms
declust
potenti
v
entranc
potenti
v
collis
energi
ev
collis
cell
exit
potenti
v
collis
ga
curtain
ga
psi
ion
spray
voltag
v
probe
temperatur
retent
time
min
meloxicam
mz
ion
min
intern
standard
piroxicam
mz
pyridinyl
amid
acylium
ion
three
standard
curv
three
set
qualiti
control
sampl
low
high
run
studi
sampl
analysi
begin
middl
end
run
qualiti
control
sampl
ngml
within
nomin
valu
standard
curv
ngml
fit
quadrat
function
weight
r
lowest
test
standard
concentr
lower
limit
quantit
carryov
assess
compar
peak
area
analyt
intern
standard
doubl
blank
inject
found
pharsightcertara
princeton
nj
usa
use
perform
pharmacokinet
pk
analysi
simul
although
actual
dose
rang
mgkg
pk
analysi
conduct
use
mean
normal
dose
mgkg
tabl
due
need
perform
studi
nonseri
fashion
extravascular
noncompartment
pk
use
determin
area
curv
trapezoid
method
mean
elimin
rate
constant
use
calcul
determin
h
sampl
first
dose
h
second
third
dose
noncompartment
analysi
observ
singl
exponenti
plasma
pk
conduct
use
result
first
meloxicam
dose
blood
sampl
intens
simul
differ
absorpt
rate
conduct
use
determin
elimin
rate
constant
vf
mlkg
mice
appear
healthi
signific
weight
chang
throughout
studi
period
skin
inject
site
remain
normal
appear
gross
lesion
evid
microscop
examin
reveal
lesion
skin
associ
drug
administr
although
blood
sampl
collect
six
male
six
femal
time
point
insuffici
sampl
volum
occur
sever
instanc
time
point
five
male
five
femal
sampl
analyz
h
six
male
six
femal
sampl
h
six
male
four
femal
sampl
h
six
male
six
femal
sampl
h
five
male
five
femal
sampl
h
six
male
six
femal
sampl
h
six
male
five
femal
sampl
h
five
male
six
femal
sampl
h
six
male
four
femal
sampl
h
six
male
six
femal
sampl
h
six
male
six
femal
sampl
h
six
male
five
femal
sampl
maximum
observ
concentr
occur
h
administr
lowest
concentr
occur
h
follow
inject
fig
sampl
collect
h
inject
mean
plasma
concentr
first
dose
found
significantli
lower
second
h
third
dose
h
tabl
male
mice
significantli
lower
plasma
concentr
femal
mice
h
time
point
tabl
concentr
similar
h
time
point
howev
signific
differ
group
h
tabl
area
curv
auc
also
found
consist
higher
femal
mice
compar
male
mice
tabl
differ
found
trough
concentr
tabl
meloxicam
establish
analges
agent
mice
use
laboratori
research
despit
common
use
subcutan
sc
inject
meloxicam
mice
sc
pharmacokinet
inform
current
limit
kendal
et
al
report
sc
dose
found
roughli
variat
rang
approxim
mgkg
employ
depend
institut
surgic
procedur
leach
et
al
miller
et
al
dose
interv
long
h
use
sc
treatment
mice
although
speci
demonstr
rapid
plasma
clearanc
dose
rout
previous
report
intraven
oral
plasma
clearanc
meloxicam
mice
approxim
higher
found
rat
human
busch
et
al
rat
human
allow
dose
clearanc
display
mice
may
requir
frequent
dose
maintain
analgesia
character
pharmacokinet
regimen
h
sc
dose
meloxicam
day
mice
intent
provid
inform
enabl
investig
achiev
effect
sc
drug
exposur
end
pharmacokinet
use
simul
meloxicam
sc
dosag
regimen
provid
coverag
primari
pharmacolog
target
suggest
publish
mous
efficaci
studi
mous
pk
sc
meloxicam
unlik
publish
oral
pk
ingrao
et
al
rapid
absorpt
short
singl
elimin
phase
observ
dose
normal
exposur
within
twofold
publish
oral
pk
suggest
good
sc
absorpt
publish
oral
bioavail
busch
et
al
distinguish
pk
characterist
sc
meloxicam
mice
rapid
plasma
clearanc
cl
agre
previou
studi
mice
shown
highest
report
iv
po
clearanc
compar
rat
dog
baboon
rabbit
busch
et
al
carpent
et
al
meloxicam
actual
drug
speci
includ
mice
defin
calcul
extract
ratio
er
base
iv
cl
hepat
blood
flow
mlminkg
davi
morri
howev
mous
cl
higher
cl
rat
dog
human
least
one
explan
higher
clearanc
high
metabol
rate
mice
lower
degre
plasma
nonspecif
bind
busch
et
al
respect
gender
result
studi
show
male
mice
overal
trend
lower
plasma
concentr
compar
femal
cmax
tabl
trough
tabl
concentr
similar
result
suggest
higher
clearanc
rate
male
mice
alter
trough
concentr
inform
impli
dose
adjust
would
requir
trough
concentr
use
pharmacokineticpharmacodyam
index
rat
demonstr
similar
gender
trend
oral
dose
male
rat
show
lower
plasma
concentr
unlik
mice
meloxicam
male
rat
shorter
compar
femal
rat
european
agenc
evalu
medicin
product
emea
studi
also
suggest
subcutan
administr
meloxicam
well
toler
mice
similar
dog
norbrook
rabbit
stei
et
al
cattl
vetoquinol
patholog
chang
observ
inject
site
mice
use
studi
result
quit
differ
document
cat
histolog
chang
hemorrhag
inflamm
myofib
atrophi
pannicul
fibrin
deposit
fibroblast
prolifer
result
singl
inject
norbrook
import
note
dilut
commerci
meloxicam
drug
product
studi
may
contribut
lack
inject
site
reaction
observ
studi
mice
sc
pk
patholog
defin
review
meloxicam
pharmacolog
initi
determin
agreement
known
efficaci
dose
vivo
drug
exposur
coverag
challeng
perform
assess
vivo
translat
vitro
ex
vivo
cox
inhibit
lack
standard
differ
assay
methodolog
led
interlaboratori
variat
determin
inhibit
constant
vane
bot
brook
et
al
blain
et
al
reason
whole
blood
assay
approach
favor
appear
superior
cellular
assay
predict
efficaci
drug
exposur
exampl
efficaci
dose
sever
cox
inhibitor
produc
total
vivo
plasma
concentr
greater
whole
blood
ic
warner
et
al
enzym
sequenc
ident
conserv
across
speci
guan
et
al
human
whole
blood
inhibit
constant
use
comparison
mous
dosag
regimen
mous
efficaci
studi
tabl
fact
human
whole
blood
inhibit
constant
appear
parallel
publish
studi
evalu
expect
rang
plasma
drug
concentr
mous
inflamm
pain
one
studi
id
oral
meloxicam
dose
mgkgday
two
dose
h
determin
zymosan
use
induc
inflammatori
marker
peritoneum
engelhardt
ed
valu
intraperiton
ip
meloxicam
mice
also
report
writh
induc
acet
acid
mgkg
santo
et
al
miranda
et
al
modest
differ
plasma
concentr
relat
dose
rout
formul
assum
sc
meloxicam
dose
rang
expect
inhibit
whole
blood
ic
nm
would
achiev
approxim
h
mgkg
sc
fig
acknowledg
import
assumpt
retrospect
analysi
propos
known
effect
meloxicam
dose
mice
reflect
correl
observ
plasma
drug
exposur
publish
whole
blood
inhibit
constant
pharmacokinet
simul
suggest
maintain
analgesia
one
dose
per
h
may
requir
fig
note
project
may
appli
formul
studi
altern
give
higher
dose
day
would
lead
high
c
max
valu
may
toler
acut
treatment
may
also
contribut
increas
risk
advers
event
simul
top
report
sc
dose
mgkg
suggest
time
whole
blood
ic
would
extend
h
assum
absorpt
rate
remain
unchang
high
dose
leach
et
al
subcutan
dose
mgkg
deliv
h
estim
cover
ic
hdose
ic
hdose
respect
fig
altern
develop
new
formul
modestli
delay
absorpt
without
affect
onset
action
could
allow
daili
dose
pk
simul
suggest
delay
max
h
could
provid
coverag
ic
hdose
ic
hdose
use
sc
dose
mgkg
respect
fig
summari
meloxicam
remain
valuabl
analges
agent
compar
medicin
pharmacokinet
profil
mice
differ
rat
speci
typic
use
dosag
regimen
assess
mous
analges
therapi
would
benefit
addit
pharmacokinet
investig
postsurg
analgesia
often
requir
day
therapeut
coverag
shown
sc
meloxicam
rapidli
elimin
mice
h
regimen
may
provid
sustain
analgesia
observ
rat
admittedli
conclus
weigh
heavili
use
human
whole
blood
inhibit
although
highli
conserv
enzym
across
speci
wide
rang
sc
meloxicam
dose
current
use
practic
propos
research
consid
modifi
prefer
meloxicam
dose
h
increas
anim
handl
toler
anticip
sc
inflammatori
respons
increas
dose
frequenc
would
minim
patholog
lesion
note
skin
daili
sc
administr
period
efficaci
endpoint
includ
studi
find
highlight
potenti
defici
way
meloxicam
analgesia
provid
mice
futur
multidos
efficaci
studi
confirm
analgesia
multipl
day
help
solidifi
postop
dose
guidelin
meloxicam
mice
author
state
complet
interest
relat
studi
phc
secur
fund
design
studi
perform
data
collect
assist
draft
manuscript
cwl
perform
pharmacokinet
analysi
statist
analysi
assist
draft
manuscript
ekf
provid
project
design
input
perform
data
collect
klb
conduct
histopatholog
analysi
contribut
patholog
descript
manuscript
author
read
approv
final
manuscript
